T1	Participants 101 151	patients with advanced or recurrent breast cancer.
T2	Participants 317 366	patients with advanced or recurrent breast cancer
T3	Participants 1361 1476	patients who were premenopausal, had no prior therapy, and were stage IV at diagnosis with an intact primary tumor.
T4	Participants 1775 1818	patients who had not received prior therapy
T5	Participants 950 978	221 patients were assessable
